Using Simvastatin Mouthwash (0.6%, 1.2% and 1.8%) on the Improvement of Clinical Parameters in Patients with Chronic Periodontitis

Periodontitis is a destructive disease that targets tooth supporting structures. Simvastatin (SMV) are inhibitors of HMG-COA reductase enzyme that have complex interaction with cholesterol metabolites, inflammatory mediators, hormones and bone metabolism, thus having direct and important effects on extent and severity of periodontitis. The present study aims to evaluate the in vivo effect of mouthwash of CHX and SMV (.6 and 1.2 and 1.8%) as a local drug-delivery agent on clinical parameters in chronic periodontitis. 50 patients were selected and categorized into five treatment groups. At initial appointment SRP were done and clinical parameters were measured and mouthwashes of SMV (0.6 - 1.2 - 1.8) and CHX and placebo distributed among groups. Measurement of clinical parameters after one month repeated for all groups and required data was collected and analyzed. SRP with SMV (0.6 – 1.2 – 1.8) significantly improve the clinical parameters (AL-BOP-PD). Mouthwash of SMV 1.2 and 1.8 and CHX in decrease of BOP and PD and AL has no significant differences (P>0.05). Mouthwash of SMV 1.2 and 1.8 and CHX has significantly differences in decrease of BOP and PD than SMV .06 and placebo (P<.05). SMV (0.6 – 1.2 – 1.8) and CHX has significantly differences in decease of AL than Normal saline. With due attention to inhibition of inflammatory cytokines with SMV on periodontitis, SMV can be good alternative for CHX in chronic periodontitis patients.